Biomerica, Inc. www.biomerica.com is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point of care in home and in physicians offices and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company s products are designed to enhance the health and well being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for diabetes, gastrointestinal disease and esoteric testing.
Quote | Biomerica Inc. (NASDAQ:BMRA)
Last: | $0.4401 |
---|---|
Change Percent: | 3.58% |
Open: | $0.43 |
Close: | $0.4249 |
High: | $0.45 |
Low: | $0.43 |
Volume: | 45,780 |
Last Trade Date Time: | 06/26/2024 03:00:00 am |
News | Biomerica Inc. (NASDAQ:BMRA)
Biomerica (NASDAQ: BMRA) , a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agree...
With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inF...
Message Board Posts | Biomerica Inc. (NASDAQ:BMRA)
Subject | By | Source | When |
---|---|---|---|
Price gaining up | Bigtrader69 | investorshub | 05/17/2023 9:26:45 AM |
Good news recently, we should start to see this one move | RadioSilent | investorshub | 05/17/2023 3:47:39 AM |
The trading | Golden Cross | investorshub | 05/16/2023 3:45:48 PM |
$BMRA Price trading | EggheadEngineer | investorshub | 05/15/2023 9:55:38 PM |
$BMRA Time for a bounce? | ALERTS100%to10000%GAIN | investorshub | 05/15/2023 8:37:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Biomerica (NASDAQ: BMRA) , a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agree...
With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inF...
Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect ™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer...